Sarah Trice joins Entos as COO

Sarah brings a wealth of experience in pharma, synthesis, and discovery software

February 22, 2021

Entos, Inc is excited to announce that Sarah Trice has joined the company as Chief Operating Officer.

Sarah Trice, Ph.D. was the Managing Director of the Cheminformatics Technologies Business Unit at Merck KGaA based in Boston Massachusetts, and brings 15 years of industrial experience in pharma, chemical synthesis, and software. Most recently at Merck, Sarah led the development and commercialization of the pioneering SYNTHIA™ Retrosynthesis Software.

Prior to joining Merck KGaA in 2014, Sarah was a senior scientist at Merck & Co., where she worked to design and evaluate novel chemotherapeutics for HIV infection. She later led an interdepartmental catalytic screening center focused on high-throughput experimentation, providing expert chemical support to fellow internal medicinal chemists.

Entos has built incredibly powerful technologies that are unparalleled in the market and it's clear that this is only the beginning. I am very excited to join the team and look forward to the great future we are building together.

Entos is committed to developing world-leading technologies for molecular discovery, and boasts a wide range of existing and evolving partnerships in the pharma and chemicals space. Sarah brings a wealth of experience in conceptualization, design, and development of commercially successful software products, along with an extensive track record of leadership in high-throughput experimentation and pharmaceuticals discovery. She brings irreplaceable depth of experience as we work together to build the next phase of Entos.

We couldn't be more excited with the recruitment of Sarah Trice to the Entos executive team. She brings a track record of scientific excellence and business leadership that will power our continued growth and innovation.